Citigroup
BIO icon

Citigroup’s Bio-Rad Laboratories Class A BIO Stock Holding History

Citigroup’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,600
Closed -$222K – 7457
2015
Q4 		$222K Buy
+1,600
New +$222K ﹤0.01% 4651

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup's BIO Position: Q1 2026 in Review

Citigroup increased its Bio-Rad Laboratories Class A (BIO) stake by 19% in Q1 2026, buying an estimated $233K and bringing the position to 5,117 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #2881.

Citigroup first reported a position in BIO in Q2 2013 and has held it in 52 quarters since. The position peaked at $14.9M in Q2 2025. 392 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Citigroup held 5,117 shares of Bio-Rad Laboratories Class A worth $1.43M as of Q1 2026.
  • Citigroup bought 808 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $233K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2881 holding.
  • Citigroup first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Bio-Rad Laboratories Class A position peaked at $14.9M in Q2 2025.
  • 392 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.